Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuli Li

Showing results (211-220 of 233) with videos related to

Pageof 24
Sort By:
Bone Marrow Transplantation|October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiationZachariah DeFilipp, Shuli Li, David Avigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
The Journal of Clinical Investigation|July 17, 2020
Immobilization after injury alters extracellular matrix and stem cell fateAmanda K Huber, Nicole Patel, Chase A Pagani, et al.
British Journal of Haematology|July 20, 2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remissionAndrew M Brunner, Shuli Li, Amir T Fathi, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Pageof 24

Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Bone Marrow Transplantation|October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiationZachariah DeFilipp, Shuli Li, David Avigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
The Journal of Clinical Investigation|July 17, 2020
Immobilization after injury alters extracellular matrix and stem cell fateAmanda K Huber, Nicole Patel, Chase A Pagani, et al.
British Journal of Haematology|July 20, 2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remissionAndrew M Brunner, Shuli Li, Amir T Fathi, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Pageof 24